Holen Sie sich die Stockscreener-App
12.30
1.76%
-0.22
Vorhandelsmarkt:
11.43
-0.87
-7.07%
Schlusskurs vom Vortag:
$12.52
Offen:
$12.35
24-Stunden-Volumen:
86,019
Relative Volume:
0.73
Marktkapitalisierung:
$367.13M
Einnahmen:
$65.42M
Nettoeinkommen (Verlust:
$-32.96M
KGV:
-9.685
EPS:
-1.27
Netto-Cashflow:
$-19.87M
1W Leistung:
-11.51%
1M Leistung:
+3.02%
6M Leistung:
+76.22%
1J Leistung:
-25.05%
1-Tages-Spanne:
$12.05
$12.64
1-Wochen-Bereich:
$12.02
$14.40
52-Wochen-Spanne:
$5.45
$18.15
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Vergleichen Sie NPCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
12.30 | 367.13M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
131.44 | 227.98B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.98 | 156.20B | 16.75B | 1.85B | 1.89B | 1.25 |
|
SYK
Stryker Corp
|
390.48 | 148.86B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
91.20 | 116.94B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.91 | 41.82B | 6.60B | 4.16B | 490.10M | 6.93 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
Head-To-Head Review: NeuroPace (NASDAQ:NPCE) vs. Aethlon Medical (NASDAQ:AEMD) - Defense World
Cantor Fitzgerald Forecasts Lower Earnings for NeuroPace - MarketBeat
Morgan Stanley Reduces Stake in NeuroPace Inc: A Strategic Portf - GuruFocus.com
JPMorgan Chase & Co. Has $84,000 Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Wells Fargo & Company Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat
NeuroPace, Inc. to Present Findings on RNS System for Focal Epilepsy at AAN 2025 Annual Meeting - Nasdaq
NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th9th - The Manila Times
Major Epilepsy Treatment Breakthrough: NeuroPace's RNS System Data Coming to AAN 2025 - StockTitan
Leerink Partnrs Estimates NeuroPace FY2029 Earnings - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Insider Martha Morrell Sells 3,200 Shares - MarketBeat
NeuroPace FY2025 EPS Forecast Reduced by Cantor Fitzgerald - Defense World
Wells Fargo & Company Boosts NeuroPace (NASDAQ:NPCE) Price Target to $17.00 - Defense World
Leerink Partnrs Predicts NeuroPace FY2029 Earnings - Defense World
NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth - Investing.com India
NeuroPace’s SWOT analysis: epilepsy device maker’s stock poised for growth By Investing.com - Investing.com Nigeria
Neuropace chief medical officer Morrell sells $48,032 in stock - MSN
NeuroPace Expects 2025 Revenue Growth -January 29, 2025 at 03:36 am EST - Marketscreener.com
Neuropace chief medical officer Morrell sells $48,032 in stock By Investing.com - Investing.com Australia
NeuroPace Projects 2025 Growth and Product Enhancements - TipRanks
NeuroPace Issues 2025 Financial Guidance Targets - The Manila Times
NeuroPace Issues 2025 Financial Guidance Targets -January 28, 2025 at 05:16 pm EST - Marketscreener.com
NeuroPace's Bold Plan to Transform Epilepsy Treatment: AI, New Markets, and 20% Growth - StockTitan
How the (NPCE) price action is used to our Advantage - Stock Traders Daily
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 26% Price Jump - Simply Wall St
Cantor Fitzgerald Comments on NeuroPace FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts NeuroPace FY2025 Earnings - MarketBeat
UBS Group Begins Coverage on NeuroPace (NASDAQ:NPCE) - Defense World
Barclays PLC Buys 16,007 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock? - Yahoo Finance
UBS sees upside for NeuroPace shares with 22% CAGR and market expansion drivers - Investing.com Australia
NeuroPace (NASDAQ:NPCE) Now Covered by Analysts at UBS Group - MarketBeat
Kck Ltd. Purchases Shares of 5,270,845 NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Receives $15.00 Average Target Price from Brokerages - Defense World
NeuroPace to Present at J.P. Morgan Healthcare Conference - TipRanks
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth By Investing.com - Investing.com Australia
NeuroPace reports preliminary Q4 revenue - MSN
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.38%
1.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):